Evaluation of the Performance of a New Pentavalent Vaccine in Poultry

Abstract

Viral inactivated vaccines play a fundamental role in animal heath, both for individual protection and for the induction of antibodies that will be passively transmitted to the progeny. Depending on the field challenges, it is eventually necessary to combine more than one etiology. Inactivated polyvalent vaccines with appropriate combinations to ensure adequate and balanced responses may induce a satisfactory and long-lasting immune response. This study aimed to evaluate the antibody responses of a new oil-based inactivated pentavalent viral vaccine for intramuscular administration containing a newly developed immunomodulator, and compare it with conventional vaccines through antibody responses to the same antigens by ELISA in successive weeks after administration. Mortality rate, weight gain, egg production and hatching were also determined to evaluate safety. The results obtained revealed significant differences (p<0.05) between the group that received the new vaccine and the control group, presenting persistent and long-lasting IgG (IgY) antibodies in specific pathogen free (SPF) chickens for 146 days. In addition, there was a statistically significant (p<0.05) difference in the serological response of the new pentavalent vaccine in commercial poultry in relation to the monovalent commercial vaccines for infectious bronchitis, avian metapneumovirus, Newcastle disease, Gumboro, and reovirus fractions. There was no change in the productive parameters evaluated when compared to the conventional vaccine or the control.